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Abstract
Background: CETP is a plasma protein that modulates atherosclerosis risk through its HDL-
cholesterol reducing action. The aim of this work was to examine the effect of the PPARα agonist,
ciprofibrate, on the CETP gene expression, in the presence and absence of apolipoprotein (apo)
CIII induced hypertriglyceridemia, and its impact on the HDL metabolism.
Results: Mice expressing apo CIII and/or CETP and non-transgenic littermates (CIII, CIII/CETP,
CETP, non-Tg) were treated with ciprofibrate during 3 weeks. Drug treatment reduced plasma
triglycerides (30-43%) and non-esterified fatty acids (19-47%) levels. Cholesterol (chol) distribution
in plasma lipoprotein responses to ciprofibrate treatment was dependent on the genotypes.
Treated CIII expressing mice presented elevation in VLDL-chol and reduction in HDL-chol.
Treated CETP expressing mice responded with reduction in LDL-chol whereas in non-Tg mice the
LDL-chol increased. In addition, ciprofibrate increased plasma post heparin lipoprotein lipase
activity (1.3-2.1 fold) in all groups but hepatic lipase activity decreased in treated CETP and non-Tg
mice. Plasma CETP activity and liver CETP mRNA levels were significantly increased in treated CIII/
CETP and CETP mice (30-100%). Kinetic studies with 3H-cholesteryl ether (CEt) labelled HDL
showed a 50% reduction in the 3H-CEt found in the LDL fraction in ciprofibrate treated compared
to non-treated CETP mice. This means that 3H-CEt transferred from HDL to LDL was more
efficiently removed from the plasma in the fibrate treated mice. Accordingly, the amount of 3H-CEt
recovered in the liver 6 hours after HDL injection was increased by 35%.
Conclusion: Together these data showed that the PPARα agonist ciprofibrate stimulates CETP
gene expression and changes the cholesterol flow through the reverse cholesterol transport,
increasing plasma cholesterol removal through LDL.
Background
Apolipoproteins (apo) CIII are small proteins mainly
found on the surface of apoB containing lipoproteins
(including VLDL, IDL and LDL), which strongly affect
their metabolism. They inhibit catabolism of these lipo-
proteins by lipoprotein-lipase (LPL) and retard their clear-
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ance from plasma by decreasing their affinity for hepatic
lipoprotein receptors [1-3]. The ability of apo CIII in
inducing hypertriglyceridemia was directly demonstrated
in transgenic mice over-expressing this protein [4]. Grow-
ing evidences have linked apo CIII concentration in VLDL
and LDL to coronary heart disease (CHD) [5,6]. Further-
more, Lee et al. [7] have reported that LDL containing apo
CIII strongly predicts coronary events in diabetic patients
independently of other lipid concentrations.
Cholesteryl ester transfer protein (CETP) promotes the
transfer of cholesteryl esters (CE) from high density lipo-
protein (HDL) to the apoB-containing lipoprotein parti-
cles, which are subsequently cleared from the circulation
by the liver. Thus, CETP plays a critical role in the intravas-
cular remodeling and recycling of HDL particles [8].
Inhibitors of CETP have been tested in human subjects
and shown to markedly increase the concentration of
HDL cholesterol while decreasing that of LDL cholesterol
and apo B [9,10], but the impact of CETP mediated lipid
transfer reactions on atherogenesis remains controversial
[11]. A large clinical trial with the CETP inhibitor torce-
trapib has been prematurely interrupted due to elevation
in mortality in the torcetrapib treated group [10]. Human
subjects with genetic CETP deficiency and high levels of
HDL-cholesterol (>60 mg/dL) showed reduced risk of
CHD, whereas CETP-deficient subjects whose HDL levels
were moderately increased (40-60 mg/dL) presented
higher risk of CHD [12]. Studies in CETP transgenic mice
have provided mixed results. The effects of CETP expres-
sion in this species can be neutral, pro- or antiatherogenic
depending upon the metabolic context [13-17].
Fibrates are drugs widely used to correct hypertriglyceri-
demia. They exert their effect by activating specific tran-
scription factors called peroxisome proliferator-activated
receptors (PPARs), which in turn alter the transcription of
several genes encoding for proteins that control lipopro-
tein metabolism. Thus, fibrates decrease plasma triglycer-
ide (TG) concentrations by activating enzymes
responsible for β-oxidation of long chain fatty acids,
reducting TG synthesis, activating lipoprotein lipase and
repressing the apo CIII expression [18,19]. Fibrates can
also alter the metabolism of HDL associated proteins. In
humans, treatment with fibrates is associated with an
increase in plasma HDL-cholesterol and apo AI concentra-
tions [20]. However, in rodents, fibrates decrease apo AI
mRNA and plasma concentrations [21] due to a polymor-
phism in the PPAR responsive elements in the apo AI gene
[22]. Bouly et al. [23] showed that fenofibrate treatment
decreased the activity of lecithin cholesterol acyl trans-
ferase (LCAT) and increased phospholipid transfer pro-
tein (PLTP), while no changes were observed hepatic
lipase (HL) activity in mice. Regarding the plasma levels
of CETP, varying results were obtained in fibrate treated
hyperlipidemic subjects, as follow: CETP decreased with
bezafibrate and fenofibrate [24-27], or did not change
with gemfibrozil, fenofibrate and bezafibrate [25,28-31],
or increased with gemfibrozil [32]. In CETP transgenic
mice, two studies reported conflicting results, estimula-
tion [33] and repression [34] of CETP expression by fenof-
ibrate. One type of fibrate largely employed in clinical
interventions, ciprofibrate, has not been evaluated regard-
ing its effect on CETP levels. Since CETP is a potent mod-
ulator of HDL levels, it is relevant to clarify whether
fibrates affect its gene expression and impact HDL metab-
olism.
Mouse models genetically modified to express specific
human genes provide a good opportunity to re-examine
the effect of established drugs and to characterize new
sites and mode of action. Thus, the aims of the present
work were to examine the effect of ciprofibrate treatment
on the CETP gene expression, in the presence and absence
of apo CIII induced hypertriglyceridemia, and its impact
on the HDL metabolism. For this purpose we used trans-
genic mice over expressing human apo CIII and CETP
genes driven by their natural promoters.
Materials and methods
Animal procedure
All animal protocols were approved by the university's
Committee for Ethics in Animal Experimentation (CEEA/
UNICAMP). The mice were housed in a temperature-con-
trolled room on a 12 h light-dark cycle and had free access
to food (standard rodent chow; Nuvital, Colombo, Brazil)
and water. Hemizygous human CETP transgenic mice,
line 5203, C57BL6/J background, expressing a human
CETP minigene under the control of its natural flanking
sequences [35] and mice overexpressing the human apol-
ipoprotein CIII, line 3707 [36] were derived from Dr. Alan
R. Tall's colony (Columbia University, New York, NY).
The pups' tail tips were utilized for screening for the pres-
ence of the CETP gene promoter by polymerase chain
reaction (PCR) DNA amplification of the -538 to -222
CETP promoter region (GeneBank U71187). Tail blood
was also drawn for determining plasma CETP activity
[37]. Apo CIII transgenic mice were screened by the level
of plasma triglycerides: transgenic > 300 mg/dL and non-
transgenic < 100 mg/dL. CETP and apoCIII transgenic
mice were crossbred to generate 4 genotypic groups:
CETP, CIII, CETP/CIII and non-transgenic. Male and
female littermates, 10-14 weeks of age, were studied after
3 weeks of treatment (v.o.) with vehicle (2% arabic gum)
or ciprofibrate (10 mg/Kg). Mice fasted overnight were
anesthetized using ketamine (50 mg/kg, i.p., Parke-Davis,
São Paulo, Brazil) and xylazine (16 mg/kg, i.p., Bayer S.A.,
São Paulo, Brazil) and killed by exsanguination through
the retroorbital plexus. Blood samples were centrifuged atLipids in Health and Disease 2009, 8:50 http://www.lipidworld.com/content/8/1/50
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2,500 × g at 4°C for 10 min. Aliquots of plasma were
stored at -80°C until analyses.
Biochemical analyses in plasma
Lipoproteins from pooled or individual plasmas of mice
were separated by fast protein liquid chromatography
(FPLC) using a HR10/30 Superose 6 column (Amersham-
Pharmacia Biotech., Uppsala, Sweden) as described previ-
ously [38]. Total cholesterol and triacylglycerols (Chod-
Pap, Roche Diagnostic GmbH., Mannheim, Germany)
and plasma free fatty acids (Wako Chemical, Neuss, Ger-
many) were determined by enzymatic-colorimetric meth-
ods according to the manufacturer's instructions. Plasma
glucose concentrations were determined by the glucose
oxidase method using the Merck Diagnostic-Biotrol® Kit
(Chennevières-les-Louvres, France) according to the
instructions. Insulin concentrations were determined by
radioimmunoassay as described previously [39] using rat
insulin as standard.
Intravascular lipases activities
Total lipase activity was determined according to Ehn-
holm & Kuusi [40]. Briefly, overnight fasted mice plasmas,
obtained before (basal) and 10 minutes after heparin I.V.
injection (100 U/Kg body weight), were incubated with a
3H-triolein/arabic gum substrate (9,10 3H (N)-triolein,
New England Nuclear, Boston, MA) in 0.2 M Tris-HCl
buffer, pH 8.5, 37°C, during 1 hour. Hepatic lipase (HL)
activity was determined in paralell tubes where the lipo-
protein lipase (LPL) was inhibited by 2 M NaCl. The
hydrolyzed labeled free fatty acids were extracted with
methanol/chloroform/heptane (1.4 : 1.25 : 1), 0.14 M
K2CO3/H3BO3, pH 10.5, dried under N2, and their radio-
activity was determined in a liquid scintillation solution
in a LS6000 Beckman Beta Counter. The LPL activity was
calculated as the difference between the total and the
hepatic lipase activities.
Cholesteryl ester transfer protein activity (exogenous 
assay)
CETP activity which reflects the plasma CETP concentra-
tion [41] was measured using an exogenous substrates
assay as previously described [37]. Briefly, a mixture of
human VLDL and LDL protein (100 μg) were incubated
with 10,000 dpm of human HDL3 labeled with [14C]-
cholesteryl ester (CE) [42] and 5 μl of mice plasma as the
source of CETP in a final volume of 100 μl. Blanks were
prepared with tris/saline/EDTA buffer (10 mM/140 mM/
1 mM), pH 7.4, and negative controls with non-transgenic
mice plasma. The incubations were carried out at 40°C for
2 hours. The apo B containing lipoproteins were precipi-
tated using a mixture of 1.6% dextran sulfate/1 M MgCl2
solution (1:1) and the radioactivity was measured in the
remaining supernatant in a scintillation solution Ultima
Gold (Eastman Kodak Co., NY) in a LS6000 Beckman
Beta Counter. The % CE transferred from [14C]-CE-HDL to
VLDL+LDL was calculated as: (dpm in the blank tube -
dpm in the plasma sample/dpm in the blank tube) × 100.
Reverse transcriptase-polymerase chain reaction (RT-
PCR) for liver CETP mRNA
Total liver RNA was extracted from ~200 mg of tissue
using Trizol reagent (Invitrogen, Grand Island, NY). The
integrity of the RNA was checked in tris-borate 1.2% aga-
rose gels stained with ethidium bromide. The amount and
purity of the RNA were determined by OD readings at 260
and 280 nm (Gene Quant, Amersham-Pharmacia Bio-
tech, Uppsala, Sweden). Genomic DNA contamination
was excluded by running a PCR on the RNA samples.
cDNA was obtained from 1 μg of total RNA by reverse
transcription using 150 ng of random primers, 10 mM of
dNTPs and 200 U of Moloney murine leukemia virus
reverse transcriptase (Superscript II; Invitrogen, Grand
Island, NY) in a final volume of 20 μl. The tubes were
incubated for 60 min at 42°C followed by 15 min at 70°C
to inactivate the enzyme. For PCR, a pair of primers was
designed to amplify the region spanning part of exon 7
and exons 8 to 14 of the human CETP cDNA, which gen-
erated a 668 bp fragment. PCR mixtures consisted of 1 μl
of cDNA, 15 pmol of primers, 2.5 U Taq polymerase and
200 μM of dNTPs in a final volume of 25 μl. A initial
denaturation at 94°C for 4 min was followed by 28 cycles
of 1 min at 94°C, 1.5 min at 58°C and 2 min at 72°C in
a Gene Amp PCR System 9700 (Perkin-Elmer, Norwalk,
CT). In parallel tubes, the same cDNA was amplified with
primers (10 pmol) for rat β-actin cDNA, which generated
a 533 bp fragment as an internal standard for the samples.
The PCR conditions for β-actin were 2 min at 94°C fol-
lowed by 23 cycles of 30 s at 94°C, 30 s at 57°C and 45 s
at 72°C. The PCR products were separated by electro-
phoresis on 1.8% agarose gels and the DNA was visual-
ized by ethidium bromide staining. The band intensities
were determined by digital scanning and quantitation
using Scion Image analysis software (Scion Corp., Freder-
ick, USA).
Kinetic studies with labeled HDL
HDL was labeled with 3H-cholesteryl oleoyl ether (Amer-
sham Biosciences, Buckinghamshire, England) as
described by Oliveira and Quintão [42]. More than 95%
of  3H-HDL was recovered in the cholesteryl ester band
after extraction and thin layer chromatography. Labeling
efficiency was about 30%. Labeled HDL was filtered in
0.22 μm Millipore membrane and used freshly. Awaken
mice received an intraperitoneal (ip) injection of 3H-HDL
(1 × 106 dpm). Blood samples (50 μl) were obtained by
the tail tip at 0.5, 1, 2, 3, 4 and 6 hours after ip injection.
Cholesterol radioactivity was determined in the superna-
tant of apo B lipoprotein precipitated plasma samples in
a liquid scintillation solution in a beta counter (BeckmanLipids in Health and Disease 2009, 8:50 http://www.lipidworld.com/content/8/1/50
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LS 6000 TA). Area under the radioactivity versus time
curve was determined as previously reported [43]. Final
plasma samples obtained by retro orbital bleeding of
anesthetized mice were submitted to FPLC, as described
above, to determine radioactivity distribution in the lipo-
protein fractions.
Results
Mice expressing apo CIII and/or CETP and non-transgenic
littermates (CIII, CIII/CETP, CETP, non-Tg) were treated
with ciprofibrate during 3 weeks. After this period, fibrate
treatment did not change body weight but relative liver
weight increased significantly (48-69%, p < 0.05) in all
four genotypic groups of mice, an expected effect for
PPARα agonists [18]. Liver and muscle fat and glycogen
content and gonadal adipose tissue weight were not
affected by ciprofibrate treatment (data not shown).
Plasma lipid, glucose and insulin concentrations before
and after ciprofibrate treatment are shown in Table 1.
Cipro treatment reduced TG (30-43%) and FFA (19-47%)
levels, did not change significantly the total cholesterol
and insulin levels, and increased (11-43%) glycemia. The
10-40% elevation in glucose concentrations was con-
firmed in a shorter 2-week period of treatment (data not
shown).
Cholesterol (chol) distribution in plasma lipoproteins is
shown in Table 2. The response to ciprofibrate treatment
was markedly dependent on the genotypes. Treated CIII
mice presented elevation in VLDL-chol (88%) and reduc-
tion in HDL-chol (45%), resulting in a 3-fold increase in
the (V+LDL)/HDL ratio. CIII/CETP mice responded to
ciprofibrate with increases in VLDL (178%) and reduc-
tions in LDL (61%) and HDL (39%). This also led to a 2-
fold increase in the (V+LDL)/HDL ratio. In ciprofibrate
treated CETP mice, there was a reduction in LDL-chol frac-
tion (29%) while in non-transgenic mice the LDL-chol
increased (122%). In both, CETP and non-Tg, there were
no changes in the (V+LDL)/HDL ratio.
As expected, ciprofibrate treatment increased plasma post
heparin LPL activity (1.3-2.1 fold) in all groups except in
CIII/CETP group (Table 3). Hepatic lipase was not altered
in apo CIII expressing mice (CIII and CIII/CETP) but
decreased significantly in normotriglyceridemic mice
(CETP and non-Tg) (Table 3).
The effects of ciprofibrate on the CETP plasma levels and
liver mRNA abundance are shown in figure 1. CIII/CETP
and CETP mice treated with ciprofibrate showed 30 and
50% increase in plasma CETP activity, respectively, and
100 and 50% increase in relative liver mRNA levels,
respectively.
We hypothesized that higher plasma CETP and lower HL
activities in fibrate treated CETP mice could change the
cholesterol flow through the reverse cholesterol transport,
increasing indirect removal through LDL and decreasing
direct removal through HDL liver uptake. Thus, 3H-
cholesteryl ether (CEt) labelled HDL was injected into cip-
rofibrate treated and control CETP mice and followed
plasma radioactivity up to 6 hours. Results are shown in
figure 2. The area under the radioactivity versus time curve
was 23% larger for the treated than for control CETP mice
(704 ± 39 vs. 572 ± 55 × 103 dpm.h, respectively, p <
0.05), indicating that greater amount of HDL remained in
the plasma of treated mice during this 6 h-period. Radio-
activity distribution in plasma lipoprotein fractions at 6 h
after the 3H-HDL injection was determined by FPLC
(Table 4). Ciprofibrate treated CETP mice presented sig-
nificantly higher levels of labeled HDL (16%) and a
marked reduction (56%) of 3H-CEt remaining in LDL
fraction (p < 0.005) when compared to control CETP
mice. This means that 3H-CEt transferred from HDL to
LDL was more efficiently removed from the plasma of
Table 1: Effect of ciprofibrate on the fasting plasma levels of lipids and glucose.
Mice groups Triglycerides
(mg/dL)
Cholesterol
(mg/dL)
Free Fatty Acids
(mmol/L)
Glucose
(mg/dL)
Insulin
(ng/ml)
CIII control 429 ± 134 (12) 124 ± 32 (12) 2.9 ± 0.5 (7) 70 ± 15 (6) 0.7 ± 0.2 (6)
treated 288 ± 140 (8)a 102 ± 39 (10) 2.2 ± 0.8 (10) 103 ± 24 (6)a 0.6 ± 0.2 (6)
CIII/CETP control 320 ± 141 (10) 100 ± 23 (10) 3.5 ± 0.8 (10) 82 ± 23 (10) 0.7 ± 0.2 (9)
treated 226 ± 142 (9) 92 ± 20 (8) 2.4 ± 0.8 (8) 91 ± 20 (8)a 0.6 ± 0.3 (6)
CETP control 86 ± 37 (10) 79 ± 27 (11) 1.7 ± 0.5 (12) 81 ± 27 (11) 0.6 ± 0.2 (8)
treated 49 ± 7 (9)b 78 ± 23 (11) 0.9 ± 0.3 (10)c 91 ± 23 (11) 0.5 ± 0.2 (12)
non-Tg control 93 ± 38 (10) 74 ± 32 (10) 1.6 ± 0.6 (13) 69 ± 32 (10) 0.4 ± 0.2 (6)
treated 56 ± 12 (9)b 93 ± 25 (10) 1.3 ± 0.4 (8) 99 ± 27 (10)a 0.6 ± 0.2 (6)
Normolipidemic (non-transgenic and CETP transgenic) and hypertriglyceridemic (CIII and CIII/CETP transgenic) mice were treated with 
ciprofibrate or vehicle (control) during 3 weeks. Mean ± SD (n). a p < 0.05; b p < 0.01; c p < 0.001 vs. control.Lipids in Health and Disease 2009, 8:50 http://www.lipidworld.com/content/8/1/50
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fibrate treated than from control CETP mice and explains
the LDL-cholesterol mass reduction observed in treated
CETP mice (Table 2). To confirm this interpretation, we
measured liver uptake of 3H-CEt 6 hours after labeled
HDL injection. Indeed, whole liver 3H-CEt content was
significantly higher in ciprofibrate treated than in control
CETP mice (36614 ± 4925 vs. 23946 ± 5745 dpm/g, p <
0.05).
Discussion
Fibrates have been extensively and successfully used as
hypotriglyceridemic drugs. However, differential effi-
ciency and lipid responses have been found, which are
probably related to the type of fibrates and to genetic var-
iation in treated patients. A paradoxal increase in total or
LDL-cholesterol in fibrate treated subjects is not very
uncommon [44-46].
In this work we showed that some important changes in
lipoprotein profile responses to ciprofibrate treatment are
largely dependent on the baseline genotype-phenotype,
specifically on the high levels of apoCIII and CETP.
Fibrate treatment reduced TG levels in both hypertriglyc-
eridemic (CIII and CIII/CETP) and normotriglyceridemic
(CETP and non-Tg) mice. Thus, this effect is independent
of the lipemic phenotype and of the presence of the pro-
teins apo CIII and CETP. However, cholesterol distribu-
tion in plasma lipoproteins was affected in a genotype
dependent manner. Fibrates induced VLDL-chol increases
and HDL-chol reductions only in apo CIII hypertriglycer-
idemic mice (CIII and CIII/CETP). Although ciprofibrate
increased plasma CETP activity, the reduction in HDL-
chol was independent of CETP, since it occurred also in
Table 2: Variation of cholesterol distribution in plasma lipoproteins after ciprofibrate treatment.
mice groups VLDL
mg/dL (%)
LDL
mg/dL (%)
HDL
mg/dL (%)
VLDL+LDL
HDL
CIII control 30.6 ± 6.0 (24.6) 16.8 ± 1.0 (13.6) 76.6 ± 6.0 (61.8) 0.6
treated 47.1 ± 2.4 (46.2)a 20.4 ± 6.0 (20.0) 34.4 ± 9.5 (33.7)a 2.0
CIII/CETP control 20.8 ± 5.0 (20,8) 26.2 ± 8.0 (26.2) 52.9 ± 10.1 (52.9) 0.9
treated 53.3 ± 8.4 (57.9)a 9.3 ± 2.0 (10.1)b 29.3 ± 8.0 (32.0)a 2.1
CETP control 1.7 ± 0.2 (2.2) 12.8 ± 2.1 (16.2) 64.5 ± 4.3 (81.6) 0.2
treated 1,8 ± 0,1(2.3) 8.9 ± 0.4 (11.5)a 67.3 ± 4.8 (86.2) 0.2
non-Tg control 3.6 ± 0.8 (4.9) 6.5 ± 2.8 (8.8) 63.8 ± 6.2 (86.3) 0.2
treated 3.3 ± 0.4 (3.6) 16.7 ± 2.2 (18.0)a 72.9 ± 5.0 (78.4)a 0.3
Normolipidemic (non-transgenic and CETP transgenic) and hypertriglyceridemic (CIII and CIII/CETP transgenic) mice were treated with 
ciprofibrate or vehicle (control) during 3 weeks. Mean ± SD, n = 6. Data were calculated as the area under VLDL, LDL and HDL peaks of the FPLC 
profile. Relative cholesterol distribution (%) is given in parenthesis. Mann Whitney test for treated vs control: a p < 0.05, b p < 0.005.
Table 3: Effect of ciprofibrate treatment on the lipoprotein 
lipase (LPL) and hepatic lipase (LH) plasma activities.
Mice groups LPL
(nmol FFA/mL/h)
LH
(nmol FFA/mL/h)
CIII control 6231 ± 279 (5) 2732 ± 2981 (5)
treated 11990 ± 610 (5)c 3829 ± 1595 (5)
CIII/CETP control 7188 ± 1244 (5) 3018 ± 550 (5)
treated 7620 ± 1993 (6) 3835 ± 611 (5)
CETP control 3906 ± 2099 (7) 2863 ± 951 (5)
treated 8378 ± 1146 (6)b 2079 ± 328 (6)a
non-Tg control 6724 ± 1126 (5) 3249 ± 806 (7)
treated 8957 ± 2984 (5)a 2706 ± 994 (5)a
Normolipidemic (non-transgenic and CETP transgenic) and 
hypertriglyceridemic (CIII and CIII/CETP transgenic) mice were 
treated with ciprofibrate or vehicle (control) during 3 weeks. Mean ± 
SD (n). a p < 0.05; b p < 0.01; c p < 0.001 vs. control.
Ciprofibrate increases CETP plasma levels and liver mRNA Figure 1
Ciprofibrate increases CETP plasma levels and liver 
mRNA. Plasma CETP levels was measured as cholesteryl 
ester (CE) transfer rates from exogenous labeled HDL to 
V+LDL acceptors (A). Panel B shows the relative hepatic 
CETP mRNA levels. Dark and open bars correspond to cip-
rofibrate treated and control CETP expressing mice, respec-
tively. Mean ± SE, n = 7-10. Student t test: *P < 0.05; **p < 
0.005.
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the absence of this protein (CIII only mice). HDL is prob-
ably reduced because in rodents fibrates decrease apo AI
synthesis [21]. The preservation of HDL-cholesterol levels
in treated normotriglyceridemic CETP and non-Tg mice is
probably associated to the decreased activity of HL
observed in these treated mice. Staels et al. [47] also
reported that fenofibrate induced reduction in HL. On the
other hand, ciprofibrate induced reductions in LDL-chol
only in the presence of CETP, either in normo- and in
hypertriglyceridemic mice (CIII/CETP and CETP),
whereas in mice that did not express CETP, the fibrate
treatment increased LDL cholesterol levels (CIII and non-
Tg).
Conflicting results have been reported regarding the effect
of fibrate treatments on the plasma CETP activity. In the
present study, we demonstrate that ciprofibrate induced
elevation of CETP plasma protein and liver mRNA levels.
The mechanism underlying the CETP gene activation is
likely transcriptional, either directly through a putative
PPAR response element in the CETP promoter [48], or
through PPARα induction of LXR which, in its turn,
enhances CETP gene transcription [49].
The opposite effect of fibrate in increasing CETP and
reducing HL levels in CETP transgenic mice led us to sup-
pose that the indirect reverse cholesterol transport would
be facilitated in these treated mice. Indeed, we observed
that higher amounts of 3H-HDL and lower 3H-LDL
remained in the plasma of ciprofibrate treated CETP mice
6 hours after the 3H-HDL injection. Thus, ciprofibrate
increased CETP mediated transfer of 3H-CEt from HDL to
LDL and accelerated plasma removal of 3H-CEt-LDL.
Since LDL receptor expression seems not to be affected by
fibrates, it is conceivable to think that ciprofibrate, or the
consequent elevated CETP activity, could improve LDL
particle affinity for its receptor, and hence speed up LDL
plasma removal process. Accordingly, Sakai et al [50]
reported that CETP deficient patients presented a retarded
plasma clearance of LDL particles because of a lower affin-
ity for their receptor. Alternatively, fibrate stimulated LPL
and repressed HL activities could have generated more
IDL. Since IDL is removed from plasma much faster than
LDL this would explain the lower levels of LDL. In addi-
tion, CETP, alone or in conjunction with HL, must play a
critical role in either IDL or LDL removal process, since
ciprofibrate did not lower the plasma LDL levels in non-
transgenic mice, which also presented higher LPL and
lower HL activities.
Higher CETP activity induced by ciprofibrate did not
result in reduction of HDL-cholesterol because plasma
removal of HDL was also impaired in fibrate treated mice.
Besides reducing HL activity, fibrate treatment may have
also diminished SRBI expression, as described by Mar-
dones et al. [51]. Nonetheless, whole liver cholesterol
uptake was increased in ciprofibrate treated CETP trans-
genic mice, suggesting that the indirect (through LDL)
reverse cholesterol transport was more effective in CETP
treated mice, as depicted in the diagram in figure 3.
Conclusion
Together these data suggest that ciprofibrate treatment of
human CETP expressing model is highly beneficial by
improving the flow of cholesterol through the indirect
reverse cholesterol transport system and preserving HDL
particles in the plasma compartment to play their pleio-
tropic antiatherogenic actions. In humans, these effects
Table 4: Ciprofibrate treatment increases LDL- and decreases 
HDL- cholesterol plasma removal. Relative 3H-cholesteryl ether 
distribution (%) in plasma lipoproteins six hours after the 
injection of 3H-HDL into ciprofibrate treated or control CETP 
transgenic mice.
Groups VLDL LDL HDL
control
(n = 5)
6.4 ± 1.8 18.3 ± 3.9 75.2 ± 4.6
treated
(n = 5)
5.2 ± 1.7 7.9 ± 1.8b 86.9 ± 6.4a
Mean ± SD. Plasma samples were fractionated by FPLC. Treated vs. 
control a p < 0.05; b p < 0.005.
Ciprofibrate treatment delays plasma removal of 3H-choles- teryl ether (3HCet) derived from HDL Figure 2
Ciprofibrate treatment delays plasma removal of 3H-
cholesteryl ether (3HCet) derived from HDL. Plasma 
kinetic of 3HCet labeled HDL injected intraperitoneally into 
ciprofibrate treated and control CETP transgenic mice was 
followed through 6 hours. Each point represents the average 
of radioactivity in plasma from 6 mice per group. The area 
under the radioactivity versus time curve was 23% larger for 
the treated than for control CETP mice (704 ± 39 vs. 572 ± 
55 × 103 dpm.h, respectively, p < 0.05).
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could be even more positive considering that fibrates also
increase apo AI synthesis.
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